



Things are moving faster than it may appear and this may be of interest to you.

Hello,

The information below may be of some interest to you.

We are very pleased to announce that two funded* pharma spin-offs, [Pherecydes-Pharma](#) and [Theranexus](#) exploiting BMSystems' co-patented discoveries are entering into clinical Phase stage in 2015 with novel therapies which are direct outputs of CADI™ Discovery, the world's first operational Mechanisms-Based Medicine platform.

These two major milestones, together with our already acquired 9 POCs and over 10 years of recurrent businesses with our clients are a strong signals confirming that BMSystems, a SME created in 2004 and profitable since 2006, has succeeded in making the "Mechanisms-Based Medicine" paradigm fully operational.

[Mechanisms-Based Medicine principles](#) enlarge and strengthen the translational medicine paradigm, generating the maximum pertinent value from scientific, medical & health data while promoting the discovery of low risk high return novel therapies.

Confirming the interest of both the medical and industrial worlds, we are invited at two events to share our vision and disclose some of our most recent achievements in neurology and psychiatry.

1. March 9-11, 2015: [Bio-Europe Spring Paris France](#): Manuel Gea, CEO of BMSystems, is invited to detail and share the Mechanisms-Based Medicine principles and their contributions to R&D during the session: Translational medicine: From discovery to early stage drug development. Monday, 9, 2015 09:00:30) Panelists:
 - François Ballet Chairman of the Board, Institute of Cardiometabolism and Nutrition (ICAN)
 - Marc Bonnefoi VP, R&D France, Sanofi
 - Manuel Gea CEO and VP R&D IS, Bio-Modeling Systems: Mechanisms-Based Medicine
 - Kurt Hertogs Platform Innovation and Incubator Strategy Leader, Johnson & Johnson Innovation, London
2. March 31, 2015. [23rd European Psychiatry Association \(EPA\) Congress](#). Vienna Dr. François Iris, CSO of BMSystems, invited to disclose our latest discoveries in the context of our European's DECIUS program with the Max Planck Institute for Psychiatry in Munich. Presentation title: Differential proteomics data integration reveals anxiety-associated molecular and cellular mechanisms in cingulate cortex synapses.

What we invented and did for ourselves, we can do for your company in the biomedical, diagnostic, Pharma, cosmetics, nutrition domains:

If you believe that the too high attrition rate should not remain a fatality, do not hesitate to contact us, we may have a solution to your issues.

For more information and access to our presentations, achievements & publications, please visit <http://www.bmsystems.net>.

Best regards

Manuel GEA
Co-founder & CEO Bio-Modeling Systems

* Pherecydes-Pharma and Theranexus funding details:

- Pherecydes-Pharma (2.6 M€ additional private funding + 3.8 M€ Phagoburn EC FP7 project grant in 2014)
- Theranexus (3.6 M€ in seed funding in 2014)

Join my networks

<http://www.linkedin.com/pub/manuel-gea/0/360/22b>

<https://twitter.com/manuelgea>

[If you do not want to receive our innovation announcements anymore](#)

*CADI (Computer Assisted Deductive Integration)